Fertility and sterility · 1994
Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morcos R N, Abdul-Malak M E, Shikora E
Аннотация
OBJECTIVE: To determine the efficacy of treatment of significant hirsutism with a GnRH agonist (GnRH-a) and estrogen and progestin replacement therapy.
DESIGN: Clinical series.
SETTING: Ambulatory gynecology clinic in a community hospital.
PATIENTS: Ten women with significant hirsutism caused by polycystic ovarian disease.
INTERVENTIONS: The patients were treated with leuprolide acetate 20 micrograms/kg per day in combination with E2 (2 mg) and medroxyprogesterone acetate (5 mg) for 6 months.
MAIN OUTCOME MEASURE: Hirsutism scores and hair growth rates determined before and upon completion of treatment protocol.
RESULTS: Hirsutism scores and hair growth rates significantly decreased by 23% and 26%, respectively. The duration of hirsutism was the only significant covariate for hirsutism scores and hair growth rates. Only two patients had minimal, irregular bleeding that was corrected by increasing the estrogen dose.
CONCLUSION: The combination of a GnRH-a and estrogen replacement therapy was an effective and well-tolerated treatment in a small group of women with significant hirsutism caused by PCOD.
DESIGN: Clinical series.
SETTING: Ambulatory gynecology clinic in a community hospital.
PATIENTS: Ten women with significant hirsutism caused by polycystic ovarian disease.
INTERVENTIONS: The patients were treated with leuprolide acetate 20 micrograms/kg per day in combination with E2 (2 mg) and medroxyprogesterone acetate (5 mg) for 6 months.
MAIN OUTCOME MEASURE: Hirsutism scores and hair growth rates determined before and upon completion of treatment protocol.
RESULTS: Hirsutism scores and hair growth rates significantly decreased by 23% and 26%, respectively. The duration of hirsutism was the only significant covariate for hirsutism scores and hair growth rates. Only two patients had minimal, irregular bleeding that was corrected by increasing the estrogen dose.
CONCLUSION: The combination of a GnRH-a and estrogen replacement therapy was an effective and well-tolerated treatment in a small group of women with significant hirsutism caused by PCOD.